Ticker: RDY

Dr. Reddy's Laboratories

Pharma Healthcare Drug Manufacturers - Specialty & Generic
Price 11.76
Reco Sell Potential 31 Risk 70 Updated 2026-09-09

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Dr. Reddy's Laboratories is a global pharmaceutical company based in India, primarily engaged in the development, manufacturing, and marketing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company operates in various segments, including pharmaceuticals, biotechnology, and consumer healthcare. Major revenue sources include sales of generic drugs in various therapeutic areas, along with contributions from its API and biosimilars divisions.

Investment Profile

The investment profile of Dr. Reddy's Laboratories suggests it may be more aligned with value investors, given its current market position and financial metrics. The stock exhibits characteristics that could appeal to those seeking stability rather than aggressive growth. Investors should consider the company's performance trends and market conditions when evaluating its suitability for their portfolios.

Fundamental metrics (experimental) Updated: 2026-09-07
EPS (TTM) — earnings per share for the last 12 months, $
39.83
Revenue QoQ — quarter-over-quarter revenue growth
6.4%
EPS surprise
-34.7%
20d volatility
0.6%
Dividend yield
0.7%
last ex-date
2026-07-24
AI recommendation changes
Date Before After Reason
2026-07-25 Sell Weak momentum and fundamentals indicate high risk.
News Page 1 of 1